MarketPulse

FDA Breakthrough Designation

2 articles
The Motley FoolThe Motley Fool··Motley Fool Transcribing

Pulse Biosciences Advances Clinical Pipeline Despite Q1 Losses

Pulse Biosciences reported Q1 2025 net losses amid clinical expansion, with $119.3M cash and three devices progressing toward commercialization milestones.
PLSEclinical trialscommercialization
BenzingaBenzinga··Vandana Singh

J&J Receives FDA Breakthrough Designation for Rybrevant Faspro in HPV-Negative Head and Neck Cancer

FDA grants J&J's Rybrevant Faspro breakthrough designation for HPV-negative head and neck cancer, potentially accelerating patient access to this new treatment option.
JNJMRKSNYTAKICLRclinical trialimmunotherapy